Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Quantifying Infection Risks in Incompatible Living Donor Kidney Transplant Recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Avery, R. K., Motter, J. D., Jackson, K. R., Montgomery, R. A., Massie, A. B., Kraus, E. S., Marr, K. A., Lonze, B. E., Alachkar, N., Holechek, M. J., Ostrander, D., Desai, N., Waldram, M. M., Shoham, S., Mehta Steinke, S., Subramanian, A., Hiller, J. M., Langlee, J., Young, S., Segev, D. L., Garonzik, J. M. 2020

Abstract

Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010-2015, categorized by desensitization intensity: none/compatible (n=260), low (0-4 plasmaphereses,n=47), moderate (5-9,n=74), and high (=10,n=94). The 1-year cumulative incidence of infection was 50.1%, 49.8%, 66.0%, and 73.5% for recipients who received none, low, moderate, and high intensity desensitization (p<0.001). The most common infections were UTI (33.5% of ILDKT vs 21.5% compatible), opportunistic (21.9% vs 10.8%), and bloodstream (19.1% vs 5.4%) (p<0.001). In weighted models, a trend towards increased risk was seen in low (wIRR=0.77 1.402.56 ,p=0.3) and moderately (wIRR=0.88 1.352.06 ,p=0.2) desensitized recipients, with a statistically significant 2.22-fold (wIRR=1.33 2.223.72 ,p=0.002) increased risk in highly desensitized recipients. Recipients with =4 infections were at higher risk of prolonged hospitalization (wIRR=2.62 3.574.88 , p<0.001) and death-censored graft loss (wHR=1.15 4.0113.95 ,p=0.03). Post-KT infections are more common in desensitized ILDKT recipients. A subset of highly desensitized patients is at ultra-high risk for infections. Strategies should be designed to protect patients from the morbidity of recurrent infections, and to extend the survival benefit of ILDKT across the spectrum of recipients.

View details for DOI 10.1111/ajt.16316

View details for PubMedID 32949093